Literature DB >> 21074875

Patterns of relapse following definitive treatment of head and neck squamous cell cancer by intensity modulated radiotherapy and weekly cisplatin.

Venla Loimu1, Juhani Collan, Leila Vaalavirta, Leif Bäck, Mika Kapanen, Antti Mäkitie, Mikko Tenhunen, Kauko Saarilahti.   

Abstract

Eighty-three patients with oropharyngeal, hypopharyngeal or laryngeal cancer were treated with concomitant cisplatin 40 mg/m(2) once a week during the radiotherapy and IMRT up to a total dose of 70 Gy. The 2-year rate of local control, overall survival and disease specific survival were 84%, 82% and 89%, respectively. The corresponding 5-year Kaplan-Meier estimates were 79%, 69% and 76%. Copyright Â
© 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21074875     DOI： 10.1016/j.radonc.2010.10.015

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN： 0167-8140            Impact factor:   6.280


  5 in total

1.  Health-related quality of life of head and neck cancer patients with successful oncological treatment.

Authors:  V Loimu; A A Mäkitie; L J Bäck; H Sintonen; P Räsänen; R Roine; K Saarilahti
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-07-02       Impact factor: 2.503

2.  Hearing and tinnitus in head and neck cancer patients after chemoradiotherapy.

Authors:  Riina Niemensivu; K Saarilahti; J Ylikoski; A Aarnisalo; A A Mäkitie
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-12-21       Impact factor: 2.503

3.  Hypopharyngeal carcinoma in Finland from 2005 to 2014: outcome remains poor after major changes in treatment.

Authors:  Harri Keski-Säntti; Marjaana Luukkaa; Timo Carpén; Anna Jouppila-Mättö; Kaisa Lehtiö; Hanna Mäenpää; Kristiina Vuolukka; Tero Vahlberg; Antti Mäkitie
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-09-12       Impact factor: 3.236

4.  Concurrent hyperfractionated accelerated radiotherapy with 5-FU and once weekly cisplatin in locally advanced head and neck cancer. The 10-year results of a prospective phase II trial.

Authors:  V Budach; E-T Becker; D Boehmer; H Badakhshi; U Jahn; K-D Wernecke; C Stromberger
Journal:  Strahlenther Onkol       Date:  2013-12-11       Impact factor: 3.621

5.  The comparison between weekly and three-weekly cisplatin delivered concurrently with radiotherapy for patients with postoperative high-risk squamous cell carcinoma of the oral cavity.

Authors:  Din-Li Tsan; Chien-Yu Lin; Chung-Jan Kang; Shiang-Fu Huang; Kang-Hsing Fan; Chun-Ta Liao; I-How Chen; Li-Yu Lee; Hung-Ming Wang; Joseph Tung-Chieh Chang
Journal:  Radiat Oncol       Date:  2012-12-18       Impact factor: 3.481
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.